Skip to main content

Reyvow Side Effects

Generic name: lasmiditan

Medically reviewed by Philip Thornton, DipPharm. Last updated on Nov 27, 2022.

Note: This document contains side effect information about lasmiditan. Some dosage forms listed on this page may not apply to the brand name Reyvow.

Applies to lasmiditan: oral tablet.

Serious side effects of Reyvow

Along with its needed effects, lasmiditan (the active ingredient contained in Reyvow) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lasmiditan:

More common

Less common

Rare

Incidence not known

Other side effects of Reyvow

Some side effects of lasmiditan may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to lasmiditan: oral tablet.

General

The most commonly reported adverse reactions have included dizziness, fatigue, paresthesia, and sedation.[Ref]

Nervous system

Vertigo, incoordination, lethargy, tremor, cognitive changes, and speech abnormalities were reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

In a clinical study evaluating driving performance 90 minutes after administration of this drug, a dose-dependent impairment of computer-based simulated driving performance was observed.

Very common (10% or more): Dizziness (up to 17%)

Common (1% to 10%): Sedation (includes somnolence), paresthesia (includes oral paresthesia, oral hypoesthesia, and hypoesthesia)

Frequency not reported: Vertigo, incoordination, lethargy, tremor, cognitive changes, speech abnormalities, impaired driving performance, serotonin syndrome

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity including angioedema, rash and photosensitivity

Cardiovascular

Chest discomfort and palpitations were reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo. A mean decrease in heart rate of 5 to 10 beats per minute was observed in patients receiving this drug, while a mean decrease of 2 to 5 beats per minute was observed in placebo patients. Blood pressure increases of 2 to 3 mmHg were observed in patients receiving 200 mg of this drug compared to a mean increase of up to 1 mmHg in placebo patients. In healthy patients over 65 years, a mean increase of 7 mmHg was observed in patients receiving this drug compared with 4 mmHg in placebo patients. By 2 hours, no difference in blood pressure compared to placebo were found. This drug has not been well studied in patients with ischemic heart disease.

Frequency not reported: Chest discomfort, palpitations, heart rate decreases, increased blood pressure

Respiratory

Dyspnea was reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

Frequency not reported: Dyspnea

Ocular

Frequency not reported: Visual impairment

Visual impairment was reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

Other

Common (1% to 10%): Fatigue (includes asthenia and malaise)

Gastrointestinal

Common (1% to 10%): Nausea and/or vomiting

Musculoskeletal

Muscle spasm and limb discomfort were reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

Common (1% to 10%): Muscle weakness

Frequency not reported: Muscle spasm, limb discomfort

Psychiatric

Frequency not reported: Feeling abnormal, anxiety, tremor, restlessness, sleep abnormalities including sleep disturbance and abnormal dreams, confusion, euphoric mood, hallucinations

Feeling abnormal, anxiety, tremor, restlessness, sleep abnormalities including sleep disturbance and abnormal dreams, confusion, euphoric mood, and hallucinations were reported in less than 2% of patients receiving this drug, but more frequently than those receiving placebo.

Frequently asked questions

References

1. Product Information. Reyvow (lasmiditan). Lilly, Eli and Company. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.